mAbs

Article	Citations
Tokenizing loops of antibodies	255
Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex	160
Correction	157
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma	132
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developability	128
Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms	124
Development of a novel, high-throughput imaged capillary isoelectric focusing-Western method to characterize charge heterogeneity of monoclonal antibody heavy and light chains	90
Biologics developability data analysis using hierarchical clustering accelerates candidate lead selection, optimization, and preformulation screening	86
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties	85
Correction	84
Selection of target-binding proteins from the information of weakly enriched phage display libraries by deep sequencing and machine learning	83
A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies	72
An antibody developability triaging pipeline exploiting protein language models	63
Overcoming claudin family homology: discovery of ARC101, a highly potent CLDN6-specific T-cell engager with a novel CD3 binder for ovarian adenocarcinoma	63
Insight into the avidity–affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn	61
Mechanistic and predictive formulation development for viscosity mitigation of high-concentration biotherapeutics	56
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies	54
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis	54
Rapid expression of therapeutic antibodies in mammalian cells via mRNA transfection	50
Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies	49
Identification of tyrosine sulfation in the variable region of a bispecific antibody and its effect on stability and biological activity	48
Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs	45
The proximity of the N- and C- termini of bovine knob domains enable engineering of target specificity into polypeptide chains	45
A mouse pancreatic organoid model to compare PD-L1 blocking antibodies	45
The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics	43

The nonglycosylated variant in therapeutic monoclonal antibodies preferentially forms large aggregates under typical thermal stresses used in forced degradation studies	43
GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery	43
Breaking barriers in antibody discovery: harnessing divergent species for accessing difficult and conserved drug targets	38
Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy	38
Impact of IgG subclass on monoclonal antibody developability	38
Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs	36
Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved products	34
In-line product quality monitoring during biopharmaceutical manufacturing using computational Raman spectroscopy	34
A highly selective TCR-mimic antibody reveals unexpected mechanisms of HBV peptide-MHC recognition and previously unknown target biology	33
Antibodies to watch in 2024	33
Structure-based calculation of excipient effects on the viscosity of concentrated antibody solutions	32
Variable domain mutational analysis to probe the molecular mechanisms of high viscosity of an IgG 1 antibody	31
Higher order receptor clustering due to the IgG3 subclass is necessary for TLR4 signaling and tolerance induction by novel human anti-TLR4 antibodies	30
Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment	28
Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production	28
Targeted protein degradation through site-specific antibody conjugation with mannose 6-phosphate glycan	27
A cell line development vector strategy for improved expression of a trispecific T-cell engager in CHO	27
Temperature and excipient mediated modulation of monoclonal antibody interactions revealed by k D, rheology, and Raman spectroscopy	27
Sequence-based engineering of pH-sensitive antibodies for tumor targeting or endosomal recycling applications	27
T cell margination: investigating the detour of T cells following forimtamig treatment in humanized mice	26
Quantifying antibody binding: techniques and therapeutic implications	26
Decoding the mannose receptor-mAb interaction: the importance of high-mannose N-glycans and glycan-pairing	26
Discovery of broadly neutralizing V H Hs against short-chain α-neurotoxins using a consensus toxin as an antigen	26
Cost and supply considerations for antibody therapeutics	25
Balancing brain exposure, pharmacokinetics and safety of transferrin receptor antibodies for delivery of neuro-therapeutics	25
Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab	25
Rapid affinity-based purification of multi-specific antibodies using Kappa Select and Protein L	25
Building a potent TREM2 agonistic, biparatopic, common light chain antibody	24
Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier	24
Comprehensive characterization of higher order structure changes in methionine oxidized monoclonal antibodies via NMR chemometric analysis and biophysical approaches	24
Evolution of phage display libraries for therapeutic antibody discovery	23
Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies	23
Antibodies to watch in 2026	23
Bivalent non-human gal-α1-3-gal glycan epitopes in the Fc region of a monoclonal antibody model can be recognized by anti-Gal-α1-3-Gal IgE antibodies	23
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics	23
Correction	23
A versatile design platform for glycoengineering therapeutic antibodies	22
Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge	22
Electrostatic properties of human germlines and biodistribution of small biologics	22
A glyco-engineering approach for site-specific conjugation to Fab glycans	22
Impact of process parameters on IgG glycosylation in CHO systems: a comprehensive quantitative analysis	22
RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties	21
IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of early immune activation	21
Hybrid IgE-IgG1 antibodies (IgEG): a new antibody class that combines IgE and IgG functionality	21
Antigenic landscapes on Staphylococcus aureus pore-forming toxins reveal insights into specificity and cross-neutralization	21
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations	21
Deciphering deamidation and isomerization in therapeutic proteins: Effect of neighboring residue	20
Humatch - fast, gene-specific joint humanisation of antibody heavy and light chains	20
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity	20
Toward generalizable prediction of antibody thermostability using machine learning on sequence and structure features	19

Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework	19
Efficient production of bispecific antibody by FAST-Ig TM and its application to NXT007 for the treatment of hemophilia A	19
A comprehensive strategy for pandemic preparedness with neutralizing monoclonal antibodies	19
Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG 1 antibodies	18
Leveraging multi-modal feature learning for predictions of antibody viscosity	18
Multidimensional maturation of antibody variable domains with machine-learning assistance	18
Engineering death resistance in CHO cells for improved perfusion culture	18
Reduction of monoclonal antibody viscosity using interpretable machine learning	17
Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows	17
Structural and biochemical differences between non-catalytic and catalytic antibodies	17
Predicting the clinical subcutaneous absorption rate constant of monoclonal antibodies using only the primary sequence: a machine learning approach	17
Predicting purification process fit of monoclonal antibodies using machine learning	17
Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function	17
International nonproprietary names for monoclonal antibodies: an evolving nomenclature system	17
Physics-based surface patch analysis for prediction of hydrophobic contribution to viscosity of mAbs	16
Combining deep mutational scanning and SPR binning approaches for large-scale epitope identification of anti-ricin antibodies	16
Translational minimal physiologically based pharmacokinetic model for transferrin receptor-mediated brain delivery of antibodies	16
A novel anti-NGF PEGylated Fab’ provides analgesia with lower risk of adverse effects	16
Development of a PRAME pMHC targeted T cell engager for solid tumor therapy	16
Alpseq : an open-source workflow to turbocharge nanobody discovery with high-throughput sequencing	16
Coactivation of Tie2 and Wnt signaling using an antibody–R-spondin fusion potentiates therapeutic angiogenesis and vessel stabilization in hindlimb ischemia	16
Discovery and characterization of two anti-PD-1 antibodies with a unique binding mechanism to human PD-1	16
Antibody markup language (AbML) — a notation language for antibody-based drug formats and software for creating and rendering AbML (abYdraw)	15
With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process	15
Full-length recombinant antibodies from Escherichia coli : production, characterization, effector function (Fc) engineering, and clinical evaluation	15
A machine learning strategy for the identification of key in silico descriptors and prediction models for IgG monoclonal antibody developability properties	15
Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers	15
Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1	15
Correction	14
Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows	14
Understanding the structure–property relationship of bispecific monoclonal antibodies with Fc site-specific substitutions	14
Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors	13
Identification and characterization of an unexpected isomerization motif in CDRH2 that affects antibody activity	13
Illuminating a biologics development challenge: systematic characterization of CHO cell-derived hydrolases identified in monoclonal antibody formulations	13
Structures of clinical antibodies bound to IL-33 uncover two distinct epitopes underlying differential efficacy	13
The impact of forced degradation conditions on mAb dimer formation and subsequent influence on aggregation propensity	13
Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy	13
NAb-seq: an accurate, rapid, and cost-effective method for antibody long-read sequencing in hybridoma cell lines and single B cells	13
Determination of ultra-trace metal-protein interactions in co-formulated monoclonal antibody drug product by SEC-ICP-MS	13
Prediction of protein biophysical traits from limited data: a case study on nanobody thermostability through NanoMelt	13
Early determination of potential critical quality attributes of therapeutic antibodies in developability studies through surface plasmon resonance-based relative binding activity assessment	12
Engineering multispecific antibodies with complete killing selectivity through the closed-loop integration of machine learning and high-throughput experimentation	12
A pH-sensitive binding modality allows successful transferrin receptor-mediated transcytosis of a bivalent antibody across brain barriers	11
IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine releas	11
Optimizing human FcRn mouse models to improve pharmacokinetic evaluation of antibody drug candidates	11
Targeted fusion of antibody-secreting cells: Unlocking monoclonal antibody production with hybridoma technology	11
An adapted consensus protein design strategy for identifying globally optimal biotherapeutics	11
Development of potent humanized TNFα inhibitory nanobodies for therapeutic applications in TNFα-mediated diseases	11
Epitope mapping of monoclonal antibodies: a comprehensive comparison of different technologies	11
A library approach for the de novo high-throughput isolation of humanized VHH domains with favorable developability properties following camelid immunization	11
Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties	11
Affinity-controlled capture and release of engineered monoclonal antibodies by macroporous dextran hydrogels using coiled-coil interactions	11
Development of novel ultra-sensitive IL-11 target engagement assays to support mechanistic PK/PD modeling for an anti-IL-11 antibody therapeutic	10
Analysis of how antigen mutations disrupt antibody binding interactions toward enabling rapid and reliable antibody repurposing	10
Computational design of therapeutic antibodies with improved developability: efficient traversal of binder landscapes and rescue of escape mutations	10
Systematic characterization of lysine glucuronidation in a bispecific antibody	10
Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions	10
Accelerating high-concentration monoclonal antibody development with large-scale viscosity data and ensemble deep learning	10
FcRn-enhancing mutations lead to increased and prolonged levels of the HIV CCR5-blocking monoclonal antibody leronlimab in the fetuses and newborns of pregnant rhesus macaques	10
Targeted chain-exchange-mediated reconstitution of a split type-I cytokine for conditional immunotherapy	10
Determining the affinities of high-affinity antibodies using KinExA and surface plasmon resonance	10
BERT2DAb: a pre-trained model for antibody representation based on amino acid sequences and 2D-structure	10
Advanced cytokine-based immunotherapies: targeted cis-delivery strategies for enhanced anti-tumor efficacy and reduced toxicity	10
Modulation of the high concentration viscosity of IgG 1 antibodies using clinically validated Fc mutations	10
The history and potential future of monoclonal antibody therapeutics development and manufacturing in four eras	10
Proceedings of the 15 th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals	10
High-throughput profiling of antibody self-association in multiple formulation conditions by PEG stabilized self-interaction nanoparticle spectroscopy	10
Development of T-cell engagers selective for cells co-expressing two antigens	10
Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease	10
Folate receptor alpha for cancer therapy: an antibody and antibody-drug conjugate target coming of age	10
Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies	10
Systematic analysis of Fc mutations designed to enhance binding to Fc-gamma receptors	9
Physicochemical and biological impact of metal-catalyzed oxidation of IgG1 monoclonal antibodies and antibody-drug conjugates via reactive oxygen species	9
Computational analysis reveals non-consensus N-glycosylation sequons in antibody Fab region	9
Large-scale data mining of four billion human antibody variable regions reveals convergence between therapeutic and natural antibodies that constrains search space for biologics drug discovery	9
Characterization of high-molecular weight by-products in the production of a trivalent bispecific 2+1 heterodimeric antibody	9
Correction	9
Characterization of free light chain impurity in a bispecific antibody	9
Modular generation of multispecific antibodies using protein trans-splicing	9
A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity	9

Process development for production of non-originator NISTmAb from CHO and NS0 cell lines	9
Targeted dual selection to optimize transposon stable pool generation of multispecifics	9
Achieving Acceleration to First-in-Human: MSD’s Learnings on Platform Method Validation Strategy	9
NAStructuralDB : structural database to facilitate computational studies of molecular modeling and recognition of proteins with special focus on antibody–antigen interactions	9
Molecular recognition requires dimerization of a VHH antibody	9
YAbS: The Antibody Society’s antibody therapeutics database	8
Successful targeting of multidrug-resistant tumors with bispecific antibodies	8
A novel in vitro serum stability assay for antibody therapeutics incorporating internal standards	8
Beyond sequence similarity: ML-powered identification of pHLA off-targets for TCR-mimic antibodies using high throughput binding kinetics	8
In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies	8
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy	8
Interplay of heavy chain introns influences efficient transcript splicing and affects product quality of recombinant biotherapeutic antibodies from CHO cells	8
Bi-functional integrin degraders cause stronger anti-proliferative effects than a blocking antibody by modulating distinct downstream signaling	8
A bispecific antibody–drug conjugate targeting CD7 and CD33 shows anti-tumor activity and improved tumor selectivity in an aggressive subtype of acute myeloid leukemia	8
Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors	8
Correction	8
Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors	8
Use of poxvirus display to select antibodies specific for complex membrane antigens	8
Fast-tracking antibody maturation using a B cell-based display system	8
Recommended nomenclature convention for the NISTCHO cell line and its product monoclonal antibody, cNISTmAb	7
Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic mice	7
Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper	7
Innovative strategies for T cell engagers for cancer immunotherapy	7
Developing drug-like single-domain antibodies (VHH) from in vitro libraries	7
P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapy	7
AbDrop-a scalable microfluidics-enabled platform for rapid discovery and functional analysis of plasma cell-derived antibodies	7
Discovery and characterization of prolactin neutralizing monoclonal antibodies for the treatment of female-prevalent pain disorders	7
Strategies for clinical dose optimization of T cell-engaging therapies in oncology	7
Pharmacokinetic and biodistribution analysis of monoclonal antibodies: a comprehensive study of antibody biodistribution and partitioning coefficients in mice	7
Structure-based engineering of a novel CD3ε-targeting antibody for reduced polyreactivity	7
Engineering hydrophobicity and manufacturability for optimized biparatopic antibody–drug conjugates targeting c-MET	7
Optimizing asymmetric antibody purification: a semi-automated process and its digital integration	7
Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain	7
Data-driven analyses of human antibody variable domain germlines: pairings, sequences and structural features	7
Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans	7
Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition	7
Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice	7
Deciphering cross-species reactivity of LAMP-1 antibodies using deep mutational epitope mapping and AlphaFold	7
AbDesign: database of point mutants of antibodies with associated structures reveals poor generalization of binding predictions from machine learning models	7
Mechanistic insights into the rational design of masked antibodies	7
3C conjugates: a highly sensitive platform for antibody internalization assessment in ADC development	7
A perspective toward mass spectrometry-based de novo sequencing of endogenous antibodies	7
HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure	6
Application of protein language models for antibody developability prediction	6
Design of orthogonal constant domain interfaces to aid proper heavy/light chain pairing of bispecific antibodies	6
ManNAc attenuates Man5 glycoform abundance through GNE-mediated metabolic channeling of UDP-GlcNAc to N-glycosylation modifications via CMP-Neu5Ac biosynthesis	6
GB18-06, a nanobody targeting GDF15, effectively alleviates weight loss and restores physical function in cachexia models	6
Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations	6
2025 Ginkgo Datapoints Antibody Developability Competition outcomes: limited model performance and a call for data standardization	6
Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer	6
Balancing the extremes for antibody developability: hydrophobic and electrostatic germline framework signatures for CDR-loop compensation	6
TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life	6
How to think about designing smart antibodies in the age of genAI: integrating biology, technology, and experience	6
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer	6